Doxycycline hyclate controlled release - POLYPID

Drug Profile

Doxycycline hyclate controlled release - POLYPID

Alternative Names: D-PLEX; Doxycycline/polymer-lipid encapsulation matrix

Latest Information Update: 15 Mar 2017

Price : $50

At a glance

  • Originator POLYPID
  • Class Antibacterials; Antimalarials; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Postoperative infections

Most Recent Events

  • 08 Mar 2017 Doxycycline hyclate controlled release - POLYPID receives Qualified Infectious Disease Product status for Postoperative infections in USA
  • 08 Mar 2017 POLYPID intends to seek regulatory approvals in USA and Europe in the coming year to conduct a phase III trial of doxycycline controlled release (D-PLEX™) in Post-cardiac surgery sternal infections
  • 08 Mar 2017 The US FDA agrees that doxycycline controlled release (D-PLEX™) can move directly into a phase III trial in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top